Study participants
unstable cardiac disease, anxiety, epilepsy, stroke, MCI, alcohol dependency, visual or auditory impairment, Parkinson’s disease, psychiatric, memory impairment, cerebrovascular disease•, schizophrenia, depression, mental retardation, head trauma
EPILEPSY, STROKE, RECRUITMENT, COLOR BLINDNESS, CEREBROVASCULAR DISEASE
Community-dwelling older adults aged 60 years and over were recruited from community senior centers and healthcare centers in the Wuxing district. Our staff distributed recruitment leaflets, and local healthcare providers also helped to make referrals to our study. Individuals who showed interest were invited for an in-person interview to screen for eligibility by three trained staff. A total of 448 potential individuals who complained of subjective memory impairment were screened in the first eligibility assessments. The second round of eligibility assessments included demographics and health characteristics (medical history, medication history, color blindness, and physical activity level), functional assessment of activities of daily, and general cognitive function. A trained neurologist-psychiatrist examined the potential participants to provide the final diagnosis of MCI. Individuals who met the following inclusion and exclusion criteria were invited to enroll (see Table 
Inclusion and exclusion criteria• Aged 60 years or older• Meets the diagnostic criterion of MCI [ - report of a relative decline in cognitive functioning duringthe past year by the participant or informant - normal general cognitive function, including the Mini-MentalState Examination score of 25 ~ 30Beijing version of the Montreal Cognitive Assessment score of ≤ 26 - intact activities of daily living (Instrumental Activities of Daily Living scale of Lawton and Brody <18) - absence of dementia• Have at least primary school education (≥ 5 years)• Absence of self-reported visual or auditory impairment and color blindness• Able to make an informed consent• A history of neurological, psychiatric, and other severe medical issues that may affect brain function (i.e., epilepsy, Parkinson’s disease, head trauma, stroke, mental retardation, depression, anxiety, schizophrenia, alcohol dependency, or other addiction)• Presence of unstable cardiac disease, significant cerebrovascular disease• Taking any medications in the past 6 months may cause impaired or improved cognitive performance• Participation in other research programs related to cognitive function during this trial.